- Report
- January 2024
- 200 Pages
Global
From €3986EUR$4,150USD£3,403GBP
- Report
- April 2023
- 129 Pages
Global
€4802EUR$5,000USD£4,100GBP
- Report
- January 2021
- 600 Pages
United States
From €2689EUR$2,800USD£2,296GBP
- Report
- October 2022
- 80 Pages
Global
From €5715EUR$5,950USD£4,878GBP
- Report
- October 2023
- 81 Pages
United Kingdom
From €3361EUR$3,500USD£2,870GBP
- Report
- March 2023
- 111 Pages
Global
From €4706EUR$4,900USD£4,018GBP
- Report
- January 2022
- 112 Pages
Global
From €4106EUR$4,275USD£3,505GBP
€4562EUR$4,750USD£3,895GBP
- Report
- June 2019
- 679 Pages
Global
€21129EUR$22,000USD£18,038GBP
- Drug Pipelines
- January 2018
- 16 Pages
Global
From €9604EUR$10,000USD£8,199GBP
- Report
- January 2021
- 124 Pages
Global
From €3458EUR$3,600USD£2,952GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €480EUR$500USD£410GBP
- Report
- January 2019
- 35 Pages
Global
From €960EUR$1,000USD£820GBP
Jevtana is a chemotherapy drug used to treat metastatic castration-resistant prostate cancer (mCRPC). It is a type of docetaxel, a chemotherapy drug that works by stopping cancer cells from dividing and growing. Jevtana is administered as an intravenous infusion every three weeks. It is used in combination with prednisone, a steroid that helps reduce inflammation and swelling.
Jevtana is approved by the US Food and Drug Administration (FDA) for the treatment of mCRPC in men who have already received other treatments. It is also approved in the European Union and other countries.
The Jevtana market is highly competitive, with several companies offering similar products. These include Sanofi, Pfizer, Astellas Pharma, and Takeda Pharmaceuticals. Each company has its own unique product offering, with different formulations, dosages, and delivery methods.
The Jevtana market is an important part of the prostate cancer drug market, providing an important treatment option for men with mCRPC. Companies in the market are continually striving to improve their products and provide better outcomes for patients. Show Less Read more